The Medacta International AMIStem-P Post-Marketing Surveillance Study

NCT04997005 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2025-05-08

No results posted yet for this study

Summary

This is a Post-Market Surveillance study of AMIStem-P femoral stem prosthesis

Conditions

  • Arthrosis
  • Traumatic Arthritis
  • Rheumatoid Polyarthritis
  • Congenital Hip Dysplasia
  • Avascular Necrosis of the Femoral Head

Interventions

DEVICE

AMIStem-P

Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant

Sponsors & Collaborators

  • Medacta International SA

    lead INDUSTRY

Principal Investigators

  • Alexandru Nebunescu-Schirliu, MD · Hôpital Jacques-Puel

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-26
Primary Completion
2029-04-30
Completion
2032-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997005 on ClinicalTrials.gov